Top

Published in:

01-06-2010 | Adis Spotlight

Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer

Authors: Karly P. Garnock-Jones, Gillian M. Keating, Lesley J. Scott

Published in: BioDrugs | Issue 3/2010

Excerpt

Breast cancer is the most common cancer in women worldwide; with >1.2 million diagnoses every year, it affects 10–12% of women.[2] It also accounts for a worldwide death toll of 500 000 per annum, making it the leading cause of cancerrelated death among women.[2] Breast cancer is more common in industrialized than in nonindustrialized countries; however, the incidence in nonindustrialized countries is rising.[2] In industrialized countries in recent years, mortality rates for breast cancer have been falling; this has been linked to the introduction of widespread screening programs and the use of adjuvant systemic treatments.[2] …

Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 2010 Jan; 70(2): 215–39PubMedCrossRef

Benson JR, Jatoi I, Keisch M, et al. Early breast cancer. Lancet 2009 Apr 25; 373(9673): 1463–79PubMedCrossRef

Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009; 27(3): 199–209PubMedCrossRef

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [online]. Available from URL://www.nccn. org/professionals/physician_gls/PDF/breast.pdf RL}ssed 2009 Jul 20]

Joy AA, Mackey JR. Adjuvant trastuzumab: progress, controversies, and the steps ahead. Curr Oncol 2006 Feb; 13(1): 8–13PubMed

Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009 Jun; 7(1–2): 4–13PubMed

Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006 Jun 7; 295(21): 2492–502PubMedCrossRef

Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009 Dec 20; 27(36): 6129–34PubMedCrossRef

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 Feb 23; 354(8): 809–20PubMedCrossRef

10.

Genentech Inc. Herceptin® (trastuzumab) US prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf [Accessed 2009 Jul 16]

11.

European Medicines Agency. Herceptin® (trastuzumab): summary of product characteristics [online]. Available from URL: rs http://www.emea.europa.eu/humandocs/PDFs/EPAR/Herceptin/H-278-PI-en.pdf [Accessed 2009 Jul 16]

12.

McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62(1): 209–43PubMedCrossRef

13.

Orman JS, Perry CM. Trastuzumab: in HER2 and hormone receptor co-positive metastatic breast cancer. Drugs 2007; 67(18): 2781–9PubMedCrossRef

14.

Plosker GL, Keam SJ. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 2006; 66(4): 449–75PubMedCrossRef

15.

McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 2008; 6 (8): 699–719CrossRef

16.

Gennari R, Menard S, Fagnoni, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004 Sep 1; 10(17): 5650–5PubMedCrossRef

17.

Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000 Apr; 6(4): 443–6PubMedCrossRef

18.

Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007 Jul 5; 357(1): 39–51PubMedCrossRef

19.

Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001 Jun 15; 61(12): 4744–9PubMed

20.

Lane HA, Motoyama AB, Beuvink I et al. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 2001; 12Suppl. 1: S21–2PubMedCrossRef

21.

Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000 May; 20(9): 3210–23PubMedCrossRef

22.

Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002 Jul 15; 62(14): 4132–41PubMed

23.

Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009 May 5; 15(5): 429–40PubMedCrossRef

24.

Mohsin SK, Weiss HL, Gutierrez MC, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005 Apr 10; 23(11): 2460–8PubMedCrossRef

25.

Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279–80PubMedCrossRef

26.

Klos KS, Zhou X, Lee S, et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003 Oct 1;98(7): 1377–85CrossRef

27.

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353 (16): 1673–84

28.

Perez E, Romond E, Suman V, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract no. 512 plus oral presentation]. J Clin Oncol 2007 Jun; 25 (18S). 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1–5; Chicago (IL)

29.

Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract no. 1 plus oral presentation]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8–11; San Antonio (TX)

30.

Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients [abstract no. 52 plus oral presentation]. 29th Annual San Antonio Breast Cancer Symposium; 2006 Dec 14–16; San Antonio (TX)

31.

Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study [abstract no. 62 plus oral presentation]. 32nd Annual San Antonio Breast Cancer Symposium; 2009 Dec 9–13; San Antonio (TX)

32.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353(16): 1659–72PubMedCrossRef

33.

Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 Jan 6; 369(9555): 29–36PubMedCrossRef

34.

Gianni L. Update of the HERA trial at 4 years' median follow-up [oral presentation]. 11th International St Gallen Breast Cancer Conference; 2009 Mar 11–14; St Gallen

35.

Perez E, Suman V, Davidson N, et al. Further analysis of NCCTG-N9831 [oral presentation]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

36.

Perez E, Suman V, Davidson N, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial [abstract no. 80 plus oral presentation]. 32nd San Antonio Breast Cancer Symposium; 2009 Dec 9–13; San Antonio (TX)

37.

Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008 Mar 10; 26(8): 1231–8PubMedCrossRef

38.

Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005 Nov 1; 23(31): 7811–9PubMedCrossRef

39.

Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007 Sep 1; 25(25): 3859–65PubMedCrossRef

40.

Rastogi P, Jeong J, Geyer C, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H) [abstract no. LBA513 plus oral presentation]. J Clin Oncol 2007; 25 (18S). 43rd annual meeting of the American Society of Clinical Oncology; 2007 Jun 1–5; Chicago (IL)

Title: Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer
Authors: Karly P. Garnock-Jones
Gillian M. Keating
Lesley J. Scott
Publication date: 01-06-2010
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 3/2010
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.2165/11204680-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2010

Technosphere® Insulin

Strategies for In Vivo Delivery of siRNAs

Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration

Dasatinib

Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic Pain

The Emerging Role of MicroRNAs as a Therapeutic Target for Cardiovascular Disease